Почти два года с COVID-19: некоторые аспекты использования антибиотиков | КМАХ

Почти два года с COVID-19: некоторые аспекты использования антибиотиков

Клиническая микробиология и антимикробная химиотерапия. 2021; 23(3):248-253

​ Ортенберг Э.А.
10.36488/cmac.2021.3.248-253
COVID-19 антибиотики эффективность резистентность
Раздел
Болезни и возбудители
Тип
Обзор
Публикация
Клиническая микробиология и антимикробная химиотерапия. 2021; 23(3):248-253

Аннотация

В данном обзоре проведена оценка влияния широкого использования антибиотиков в алгоритмах фармакотерапии пациентов с COVID-19 на результаты лечения. Исходя из анализа наиболее масштабных публикаций 2020–2021 гг., можно сделать вывод, что опыт применения антимикробных препаратов (включая препараты широкого спектра) в качестве компонента схем лечения у пациентов с COVID-19 не выявил их реального жизнеспасающего эффекта. Несмотря на то что в ряде случаев назначение антибиотиков остается неизбежным, необходимо прилагать усилия по сокращению их чрезмерного использования.

Ортенберг Эдуард Анатольевич

ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России, Тюмень, Россия

  • 1. Ginsburg A.S., Klugman K.P. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Health. 2020;8(12):e1453-e1454. DOI: 10.1016/S2214-109X(20)30444-7
  • 2. Mahoney A.R., Safaee M.M., William M., Wuest W.M., Furst A. The silent pandemic: emergent antibiotic resistances following the global response to SARS-CoV-2. iScience. 2021;102304. DOI: 10.1016/j.isci.2021.102304
  • 3. Interim methodological recommendations. Prevention, diagnostics and treatment of new coronavirus infection (COVID-19). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf Russian. (МЗ РФ Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 10 (08.02 2021), 260 c. Доступно по адресу: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf )
  • 4. Drożdżal S., Rosik J., Lechowicz K., Machaj F., Kotfis K., Ghavamiet S., et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020;53:100719. DOI: 10.1016/j.drup.2020.100719
  • 5. Trivedi N., Verma A., Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020;24(23):12593-12608. DOI: 10.26355/eurrev_202012_24057
  • 6. Shah R.R. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. J Clin Pharm Ther. 2021;46(1):17-27. DOI: 10.1111/jcpt.13267
  • 7. Bassetti M., Giacobbe D.R., Aliberti S., Barisione E., Centanni S., De Rosa F., et al. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020;26(7):880-894. DOI: 10.1016/j.cmi.2020.04.031
  • 8. Peng X., Xu X., Li Y., Cheng L., Zhou X., Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9. DOI: 10.1038/s41368-020-0075-9
  • 9. Lippi G., Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190-191. DOI: 10.1016/j.cca.2020.03.004
  • 10. Ruuskanen O., Lahti E., Jennings L.C., Murdoch D.R. Viral pneumonia. Lancet. 2011;377(9773):12641275. DOI: 10.1016/s01406736(10)61459-6
  • 11. Klein E.Y., Monteforte B., Gupta A., Jiang W., May L., Hsieh Y., Dugas A. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016;10(5):394-403. DOI: 10.1111/irv.12398
  • 12. Chen N., Zhou M., Dong X., Qu J., Gong F., Hanet Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. DOI: 10.1016/s0140-6736(20)30211-7
  • 13. Zhang G., Hu C., Luo L., Fang F., Chen Y., Liet J., et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. DOI: 10.1016/j.jcv.2020.104364
  • 14. Rawson T.M., Moore L., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-2468. DOI: 10.1093/cid/ciaa530
  • 15. Kim Y.G., Park J.H., Reimer T., Baker D.P., Kawai T., Kumar H., et al. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe. 2011;9:496-507. DOI: 10.1016/j.chom.2011.05.006
  • 16. Lai C.C., Wang C.Y., Hsueh P.R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53(4):505-512. DOI: 10.1016/j.jmii.2020.05.013
  • 17. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. DOI: 10.1016/s0140-6736(20)30566-3
  • 18. Huttner B., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-810. DOI: 10.1016/j.cmi.2020.04.024
  • 19. Hughes S., Troise O., Donaldson H., Mughal N., Moore L. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26:1395-1399. DOI: 10.1016/j.cmi.2020.06.025
  • 20. Garcia-Vidal C., Sanjuan G., Moreno-García E., PuertaAlcalde P., Garcia-Pouton N., Chumbita M., et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83-88. DOI: 10.1016/j.cmi.2020.07.041
  • 21. Langford B.J., So M., Raybardhan S., Leung V., Soucy J.P., Westwoodet D., et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis .Clin Microbiol Infect. 2021;27(4):520-531. DOI: 10.1016/j.cmi.2020.12.018
  • 22. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. National Institute for Health and Care Excellence (NICE), 2020. Available at: www.nice.org.uk/guidance/ng173/chapter/4-Assessing-the-ongoing-needforantibiotics.
  • 23. Zaitsev A.A. Letter to the editors. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2020;22(2):84-86. Russian. (Зайцев А.А. Письмо в редакцию. Клиническая микробиология и антимикробная химиотерапия. 2020;22(2):84-86.) DOI: 10.36488/cmac.2020.2.84-86
  • 24. World Health Organization. Clinical management of COVID-19 interim guidance, May 2020. Geneva: World Health Organization; 2020. Available at: www.who.int/publications-detail/clinical-management-of-covid-19.
  • 25. Langford B.J., So M., Raybardhan S., Leung V., Westwood D., MacFaddenet D., et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622-1629. DOI: 10.1016/j.cmi.2020.07.016
  • 26. Huang C., Soleimani J., Herasevich S., Pinevich Y., Pennington K., Dong Y., et al. Clinical characteristics, treatment, and outcomes of critically ill patients with COVID-19: a scoping review. Mayo Clin Proc. 2021;96(1):183-202. DOI: 10.1016/j.mayocp.2020.10.022
  • 27. Chjng W.H., Saha B.K., Ramani A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection. 2021;1-15. DOI: 10.1007/s15010-021-01602-z
  • 28. Sieswerda E., de Boer M., Bonten M., Boersma W., Jonkers R., Alevaet R., et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021;27(1):61-66. DOI: 10.1016/j.cmi.2020.09.041
  • 29. Nair G.B., Niederman M.S. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther. 2021;217:107663. DOI: 10.1016/j.pharmthera.2020.107663
  • 30. Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI: 10.1164/rccm.201908-1581ST
  • 31. Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949
  • 32. Mehra M., Desai S., Ruschitzka F., Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;S0140-6736(20)31180-6. DOI: 10.1016/S0140-6736(20)31180-6
  • 33. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from in vitro antiinflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;68:479-503. DOI: 10.1007/s00228-011-1161-x
  • 34. Firth A., Prathapan P. Azithromycin: the first broad-spectrum therapeutic. Eur J Med Chem. 2020;207:112739. DOI: 10.1016/j.ejmech.2020.112739
  • 35. Albani F., Fusina F., Giovannini A., Ferretti P., Granato A., Prezioso C., et al. Impact of azithromycin and/or hydroxychloroquine on hospital mortality in COVID-19. J Clin Med. 2020;9:2800. DOI: 10.3390/jcm9092800
  • 36. Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S., Rivera D., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907-1918. DOI: 10.1016/S0140-6736(20)31187-9
  • 37. Furtado R.H., Berwanger O., Fonseca H.A., Corrêa T.D., Ferraz L.R., Lapa M.G., et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959-967. DOI: 10.1016/S0140-6736(20)31862-6
  • 38. Rosenberg E.S., Dufort E.M., Udo T., Wilberschied L.A., Kumar J., Tesoriero J., et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493-2502. DOI: 10.1001/jama.2020.8630
  • 39. Gyselinck I., Janssens W., Verhamme P., Vos R.B. Rationale for azithromycin in COVID-19: an overview of existing evidence. MJ Open Respir Res. 2021;8(1):e000806. DOI: 10.1136/bmjresp-2020-000806
  • 40. Sarayani A., Cicali B., Henriksen C., Brown J. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. 2021;17(2):483-486. DOI: 10.1016/j.sapharm.2020.04.016
  • 41. Michaud V., Dow P., Sweilem B., Deodhar M., Arwood M., Cicali B., Turgeon J. Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs. Clin Transl Sci. 2021;14(1):20-28. DOI: 10.1111/cts.12882
  • 42. Zhang J., Ma X., Yu F., Liu J., Zou F., Pan T., Zhang H. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020.02.05.935387. DOI: 10.1101/2020.02.05.935387
  • 43. Mosquera-Sulbaran J.A., Hernández-Fonseca H. Tetracycline and viruses: a possible treatment for COVID-19? Arch Virol. 2021;166(1):1-7. DOI: 10.1007/s00705-020-04860-8
  • 44. Huttner B.D., Catho G., Pano-Pardo J.R., Pulcini C., Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! J Clin Microbiol Infect. 2020;26(7):808-810. DOI: 10.1016/j.cmi.2020.04.024
  • 45. Wagner C.E., Prentice J.A., Saad-Roy C.M., Yang L., Grenfell B.T., Levin S.A., Laxminarayan R. Economic and behavioral influencers of vaccination and antimicrobial use. Front Public Health. 2020;8:614113. DOI: 10.3389/fpubh.2020.614113
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились